|
| 产品描述 |
| Linifanib, also known as ABT-869, is an orally bioavailable, small-molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Linifanib inhibits members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families; it exhibits much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. This agent does not have a general antiproliferative effect due to its high dose requirement. However, linifanib may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as fms-related tyrosine kinase receptor-3 (FLT3). |
| 化学结构 |
 |
| 化学名称 |
| N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea |
| SMILES Code |
| O=C(N)N(C1=CC=C(C2=CC=CC3=C2C(N)=NN3)C=C1)C4=CC(C)=CC=C4F |
| 基本信息 |
产品编号:XM372
产品名称:Linifanib (ABT-869)
别名:ABT869; ABT 869; ABT-869; Linifanib
CAS#:796967-16-3
分子式:C21H18FN5O
精确分子量:375.14954
分子量:375.4
|
| 物化性质 |
外观: 固体粉末
纯度: >98%
运输信息: 非危险化学品，适于常温或冰袋运输。
储存条件: 低温，干燥，避光。
溶解性: 溶于DMSO, 不溶于水
储存期限:3年 -20℃固体储存
2 年 -80℃ 溶液储存 |
该产品只供科研使用，不能给病人提供。
|
|
|
